Paul Tudor Jones's BMY Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 1.2 M shares of Bristol-Myers Squibb Company (BMY) worth $54.11 M, representing 0.09% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in BMY, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2022, adding 2.27 M shares. Largest reduction occurred in Q4 2022, reducing 2 M shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +225,000 | New Buy | 225,000 | $46.28 |
| Q4 2013 | -125,000 | Reduce 55.56% | 100,000 | $53.15 |
| Q1 2014 | -83,651 | Reduce 83.65% | 16,349 | $51.93 |
| Q2 2014 | +18,363 | Add 112.32% | 34,712 | $48.51 |
| Q3 2014 | -19,843 | Reduce 57.16% | 14,869 | $51.18 |
| Q4 2014 | -14,869 | Sold Out | 14,869 | $0.00 |
| Q1 2015 | +164,515 | New Buy | 164,515 | $64.50 |
| Q2 2015 | -138,644 | Reduce 84.27% | 25,871 | $66.52 |
| Q3 2015 | -9,551 | Reduce 36.92% | 16,320 | $59.19 |
| Q4 2015 | -5,920 | Reduce 36.27% | 10,400 | $68.75 |
| Q1 2016 | +1,400 | Add 13.46% | 11,800 | $63.90 |
| Q2 2016 | +2,000 | Add 16.95% | 13,800 | $73.55 |
| Q3 2016 | +103,087 | Add 747.01% | 116,887 | $53.92 |
| Q4 2016 | -93,110 | Reduce 79.66% | 23,777 | $58.46 |
| Q1 2017 | -2,076 | Reduce 8.73% | 21,701 | $54.38 |
| Q2 2017 | +60,685 | Add 279.64% | 82,386 | $55.73 |
| Q3 2017 | +42,578 | Add 51.68% | 124,964 | $63.74 |
| Q4 2017 | -95,178 | Reduce 76.16% | 29,786 | $61.27 |
| Q1 2018 | +38,789 | Add 130.23% | 68,575 | $63.24 |
| Q2 2018 | +18,143 | Add 26.46% | 86,718 | $55.34 |
| Q3 2018 | +55,031 | Add 63.46% | 141,749 | $62.08 |
| Q4 2018 | -81,904 | Reduce 57.78% | 59,845 | $51.98 |
| Q1 2019 | +201,011 | Add 335.89% | 260,856 | $47.71 |
| Q2 2019 | -171,836 | Reduce 65.87% | 89,020 | $45.35 |
| Q3 2019 | -89,020 | Sold Out | 89,020 | $0.00 |
| Q4 2020 | +99,016 | New Buy | 99,016 | $62.03 |
| Q1 2021 | -40,784 | Reduce 41.19% | 58,232 | $63.13 |
| Q2 2021 | -58,232 | Sold Out | 58,232 | $0.00 |
| Q3 2021 | +194,944 | New Buy | 194,944 | $59.17 |
| Q4 2021 | -186,135 | Reduce 95.48% | 8,809 | $62.32 |
| Q1 2022 | -8,809 | Sold Out | 8,809 | $0.00 |
| Q2 2022 | +2.28 M | New Buy | 2.28 M | $2.14 |
| Q3 2022 | -4,150 | Reduce 0.18% | 2.28 M | $2.18 |
| Q4 2022 | -2 M | Reduce 87.79% | 277,869 | $0.07 |
| Q1 2023 | -266,633 | Reduce 95.96% | 11,236 | $0.07 |
| Q2 2023 | +16,254 | Add 144.66% | 27,490 | $63.95 |
| Q3 2023 | -27,490 | Sold Out | 27,490 | $0.00 |
| Q4 2023 | +767,451 | New Buy | 767,451 | $51.31 |
| Q1 2024 | -767,451 | Sold Out | 767,451 | $0.00 |
| Q2 2024 | +2 M | New Buy | 2 M | $41.53 |
| Q3 2024 | -2 M | Sold Out | 2 M | $0.00 |
| Q4 2024 | +10,960 | New Buy | 10,960 | $56.56 |
| Q1 2025 | -10,960 | Sold Out | 10,960 | $0.00 |
| Q3 2025 | +1.2 M | New Buy | 1.2 M | $45.10 |
Paul Tudor Jones's Bristol-Myers Squibb Company Investment FAQs
Paul Tudor Jones first purchased Bristol-Myers Squibb Company (BMY) in Q3 2013, acquiring 225,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Bristol-Myers Squibb Company (BMY) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Bristol-Myers Squibb Company (BMY) was in Q2 2022, adding 2,279,686 shares worth $4.88 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 1,199,793 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $54.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.09% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Bristol-Myers Squibb Company (BMY) was 2,279,686 shares, as reported at the end of Q2 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.